CervoMed (CRVO) EBITDA Margin (2011 - 2025)
CervoMed (CRVO) posted EBITDA Margin of 95479.25% for Q4 2025, down 3728.68% sequentially from 2493.79% in Q3 2025, and down 9514433.0% YoY from N/an in Q4 2024.
CervoMed (CRVO) EBITDA Margin (2011 - 2025) Analysis & Trends
CervoMed has reported EBITDA Margin for 6 years, with the latest figure at 95479.25% in Q4 2025.
- Quarterly EBITDA Margin fell 9514433.0% year-over-year to 95479.25% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 1488.86% (down 126395.0% YoY) and the FY2025 annual result came in at 706.22%, down 51905.0% from the prior year.
- EBITDA Margin eased to 95479.25% in Q4 2025 per CRVO's latest filing, from 2493.79% in the prior quarter.
- Over five years, EBITDA Margin peaked at 71.57% in Q2 2023 and troughed at 95479.25% in Q4 2025.
- A 3-year average of 8324.04% and a median of 225.9% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 924 bps in 2024, then slumped 9514433 bps in 2025.
- Over 3 years, EBITDA Margin stood at 99.59% in 2023, then tumbled by 236 bps to 334.91% in 2024, then tumbled by 28409 bps to 95479.25% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 95479.25%, 2493.79%, and 376.41% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 19.75% |
| 10 | CervoMed | 27.05 Mn | 27.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -95,479.25% |
| Sep 30, 2025 | -2,493.79% |
| Jun 30, 2025 | -376.41% |
| Mar 31, 2025 | -276.55% |
| Dec 31, 2024 | -334.91% |
| Sep 30, 2024 | -278.19% |
| Jun 30, 2024 | -91.06% |
| Mar 31, 2024 | -110.55% |
| Dec 31, 2023 | -99.59% |
| Sep 30, 2023 | -175.25% |
| Jun 30, 2023 | -71.57% |
| Mar 31, 2023 | -101.31% |
| Jun 30, 2013 | -11,298.21% |
| Sep 30, 2012 | -2,390.40% |
| Jun 30, 2012 | -2,390.40% |
| Mar 31, 2012 | -1,474.33% |
| Dec 31, 2011 | -2,672.07% |
| Sep 30, 2011 | -1,654.78% |